NASDAQ:OCUL

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$5.07

-0.07 (-1.36%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $4.94
▼
$5.29
50-Day Range: $3.87
▼
$6.27
52-Week Range: $2.57
▼
$6.53

Volume: 640,329 shs
Average Volume: 1.52 million shs
Market Capitalization: $392.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

Institutional Ownership

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating: Buy
3.33 Rating Score
Upside/Downside: 126.8% Upside
$11.50 Price Target
Short Interest: Bearish
5.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.01
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$161,777 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.03) to ($0.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

316th out of 1,002 stocks

Pharmaceutical Preparations Industry

136th out of 488 stocks

3.7

Analyst's Opinion

Consensus Rating
Ocular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.50, Ocular Therapeutix has a forecasted upside of 126.8% from its current price of $5.07.
Amount of Analyst Coverage
Ocular Therapeutix has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.78% of the outstanding shares of Ocular Therapeutix have been sold short.
Short Interest Ratio / Days to Cover
Ocular Therapeutix has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ocular Therapeutix has recently increased by 12.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ocular Therapeutix does not currently pay a dividend.
Dividend Growth
Ocular Therapeutix does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ocular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Ocular Therapeutix is -2.01.

2.7

News and Social Media Coverage

News Sentiment
Ocular Therapeutix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $161,777.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Ocular Therapeutix is held by insiders.
Percentage Held by Institutions
55.40% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.03) to ($0.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ocular Therapeutix is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ocular Therapeutix is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ocular Therapeutix has a P/B Ratio of 11.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

March 16, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Aura Biosciences Inc (AURA)

March 11, 2023 | finance.yahoo.com

Downgrade: Here's How Analysts See Ocular Therapeutix, Inc. (NASDAQ:OCUL) Performing In The Near Term

March 28, 2023 | The Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 9, 2023 | msn.com

Looking Into Ocular Therapeutix's Return On Capital Employed

March 8, 2023 | finance.yahoo.com

Ocular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

March 8, 2023 | finance.yahoo.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript

March 8, 2023 | finance.yahoo.com

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

March 8, 2023 | msn.com

The Latest Analyst Ratings for Ocular Therapeutix

March 28, 2023 | Porter & Company (Ad)

A strange force is brewing…

An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit.

March 7, 2023 | finance.yahoo.com

Q4 2022 Ocular Therapeutix Inc Earnings Call

March 6, 2023 | finance.yahoo.com

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

March 6, 2023 | msn.com

Ocular Therapeutix Q4 GAAP EPS, revenue beats, guidance below consensus

March 6, 2023 | finance.yahoo.com

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

February 28, 2023 | finance.yahoo.com

Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference

February 26, 2023 | marketwatch.com

Global Ocular Drug Delivery Technology Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReports

February 26, 2023 | marketwatch.com

Global Ocular Drug Delivery Market Research Report 2023 by Product, Application, End-users, Region And Global Forecast to 2030 By VMReports

February 22, 2023 | marketwatch.com

Hydrogel Market In 2023 By In-depth Analysis of Revenue Forecast and Competitive Landscape 2028

February 22, 2023 | marketwatch.com

Global Ocular Drug Delivery Market International Competition and Emerging Business Opportunities to 2028

February 21, 2023 | finance.yahoo.com

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results

February 16, 2023 | finance.yahoo.com

Why Shares of Ocular Therapeutix Jumped This Week

February 14, 2023 | marketwatch.com

Ocular Pain Market : Future Scope, Demand, Perceptive and Comprehensive Analysis By 2028

February 13, 2023 | markets.businessinsider.com

Berenberg Bank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

February 13, 2023 | msn.com

Ocular Soars after Positive Interim Data

February 13, 2023 | msn.com

4 stocks to watch on Monday: Bally's, Ocular Therapeutix and more

February 13, 2023 | marketwatch.com

Ocular Therapeutix Shares Up 14% on OTX-TKI Retinal Treatment Data

February 13, 2023 | msn.com

Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial

February 11, 2023 | finance.yahoo.com

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings: 11/08/2021
Today: 3/28/2023
Next Earnings (Estimated): 5/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCUL
CUSIP: N/A
CIK: 1393434
Web: www.ocutx.com
Phone: (781) 357-4000
Fax: 781-357-4001
Employees: 228
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.50
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +126.8%
Consensus Rating: Buy
Rating Score (0-4): 3.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,040,000.00
Net Margins: -137.95%
Pretax Margin: -137.95%
Return on Equity: -127.95%
Return on Assets: -43.48%

Debt

Debt-to-Equity Ratio: 1.53
Current Ratio: 4.13
Quick Ratio: 4.07

Sales & Book Value

Annual Sales: $51.49 million
Price / Sales: 7.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 11.02

Miscellaneous

Outstanding Shares: 77,509,000
Free Float: 73,789,000
Market Cap: $392.97 million
Optionable: Optionable
Beta: 1.28

Key Executives

Antony Mattessich
President, Chief Executive Officer & Director

Donald Notman
Chief Financial Officer

Peter Jarrett
Chief Scientific Officer

Rabia Gurses Ozden
Chief Medical Officer

Karen-Leigh Edwards
Senior Vice President-Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings or view top-rated stocks.
What is Ocular Therapeutix's stock price forecast for 2023?: 3 equities research analysts have issued 1-year price objectives for Ocular Therapeutix's shares. Their OCUL share price forecasts range from $10.00 to $14.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price.
View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts.
How have OCUL shares performed in 2023?: Ocular Therapeutix's stock was trading at $2.81 at the beginning of 2023. Since then, OCUL shares have increased by 80.4% and is now trading at $5.07.
View the best growth stocks for 2023 here.
When is Ocular Therapeutix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our OCUL earnings forecast.
How were Ocular Therapeutix's earnings last quarter?: Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 127.95% and a negative net margin of 137.95%. During the same quarter in the prior year, the company posted ($0.17) EPS.
What ETFs hold Ocular Therapeutix's stock?: ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Pharmaceuticals ETF (XPH), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ) and
What guidance has Ocular Therapeutix issued on next quarter's earnings?: Ocular Therapeutix updated its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $69.98 million.

What other stocks do shareholders of Ocular Therapeutix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).
What is Ocular Therapeutix's stock symbol?: Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
Who are Ocular Therapeutix's major shareholders?: Ocular Therapeutix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Summer Road LLC (7.95%), Opaleye Management Inc. (7.89%), Deltec Asset Management LLC (2.41%), Geode Capital Management LLC (1.83%), Emerald Advisers LLC (1.25%) and Emerald Mutual Fund Advisers Trust (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends.
How do I buy shares of Ocular Therapeutix?: Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ocular Therapeutix's stock price today?: One share of OCUL stock can currently be purchased for approximately $5.07.
How much money does Ocular Therapeutix make?: Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $392.97 million and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-71,040,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
How many employees does Ocular Therapeutix have?: The company employs 228 workers across the globe.
How can I contact Ocular Therapeutix?: Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ocular Therapeutix - OCUL Stock Forecast, Price & News

Ocular Therapeutix MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Ocular Therapeutix (NASDAQ:OCUL) Stock

OCUL Stock News Headlines

OCUL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OCUL Stock - Frequently Asked Questions

Overall MarketRank^™